US Bancorp
TERN

US Bancorp’s Terns Pharmaceuticals TERN Stock Holding History

US Bancorp’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Buy
5,190
+583
+13% +$23.9K ﹤0.01% 1843
2025
Q4 		$186K Buy
4,607
+4,066
+752% +$94K ﹤0.01% 2065
2025
Q3 		$4.06K Sell
541
-1,130
-68% -$7.21K ﹤0.01% 3596
2025
Q2 		$6.23K Sell
1,671
-779
-32% -$2.43K ﹤0.01% 3569
2025
Q1 		$6.76K Buy
+2,450
New +$10K ﹤0.01% 3564
2024
Q3 		– Sell
-600
Closed -$4.09K – 4180
2024
Q2 		$4.09K Sell
600
-95
-14% -$575 ﹤0.01% 3576
2024
Q1 		$4.56K Buy
695
+309
+80% +$2.02K ﹤0.01% 3547
2023
Q4 		$2.5K Buy
386
+89
+30% +$471 ﹤0.01% 3664
2023
Q3 		$1.49K Buy
+297
New +$1.89K ﹤0.01% 3708

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

US Bancorp's TERN Position: Q1 2026 in Review

US Bancorp increased its Terns Pharmaceuticals (TERN) stake by 13% in Q1 2026, buying an estimated $23.9K and bringing the position to 5,190 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #1843.

US Bancorp first reported a position in TERN in Q3 2023 and has held it in 9 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • US Bancorp held 5,190 shares of Terns Pharmaceuticals worth $274K as of Q1 2026.
  • US Bancorp bought 583 Terns Pharmaceuticals shares in Q1 2026, an estimated $23.9K.
  • Terns Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #1843 holding.
  • US Bancorp first reported a position in Terns Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.